Skip to content Skip to footer

Ivermectine als Behandelprotocol voor Huisartsen

Ivermectine is het alternatief voor Vaccineren, hierdoor vervalt de tijdelijke vergunning voor de experimentele vaccinaties.

Laat de Huisartsen Ivermectine voorschrijven voor de indicatie: Covid-19. Formuleer dit onmiddelijk als behandelprotocol.

Petitie

Ivermectine als Behandelprotocol voor Huisartsen

Covid-19 wordt succesvol bestreden en voorkomen met het middel Ivermectine, Aldus meerdere wetenschappelijke publicaties.(zie onderaan deze pagina).

Bureaucratie mag levensreddende behandelingen middels toepassing van het juiste medicijn niet in de weg staan.

Laat de Huisartsen Ivermectine voorschrijven voor de indicatie: Covid-19. Formuleer dit onmiddelijk als behandelprotocol.

Ivermectine is het alternatief voor Vaccineren, hierdoor vervalt de tijdelijke vergunning voor de experimentele vaccinaties.
Omdat Ivermectine preventieve werking heeft kan Nederland bevrijd worden van de mens- onterende en slopende "preventieve"maatregelen.

We kunnen samen Nederland bevrijden, maar dan moet je wel je stem laten horen.
Teken voor behandeling met Ivermectine.

Teken, deel, Doneer!

Gericht aan: SWAB, NHG, Minister VWS (H.deJonge), Tweede Kamer
Wij: Het Volk
Constateren: Dat de wetenschappelijke wereld voor Covid-19 een Preventief en Curatief middel heeft gevonden in het reeds jarenlang bekende, beproefde en volkomen veilige middel; Ivermectine.
En Verzoeken: Dat Ivermectine wordt erkent als alternatief op Vaccineren en; Dat dit Ivermectine per direct als behandelprotocol voor Covid-19 door alle huisartsen moet worden voorgeschreven.

Ivermectine

704 handtekeningen
Laatste Handtekeningen
704 Ms. annelies R. nederland jun 07, 2021
703 Mr. Silas G. Gelderland mei 20, 2021
702 Mrs. Elly G. Noord-brabant mei 15, 2021
701 Mevr Pauline M. Utrecht mei 11, 2021
700 Dhr Harry V. NOORD-Brabant apr 13, 2021
699 Mevr Thea V. Noord holland apr 01, 2021
698 Dhr Martijn S. Limburg mrt 31, 2021

Deel deze petitie

Share on email
Email
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

Doneren

Of help ons middels een donatie

Bronnen

Peer-reviewed publicaties

Ahmed, S. et al. A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International Journal of Infectious Diseases, 2020; December
https://www.sciencedirect.com/science/article/pii/S1201971220325066

Alam, M. T. et al. Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Study. European Journal of Medical & Health Sciences, 2020; vol. 2 (6)
https://ejmed.org/index.php/ejmed/article/view/599

Alam, M.T. et al. A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline. Journal of Bangladesh College of Physicians and Surgeons, 2020; vol. 38: p.10-15
https://www.researchgate.net/publication/343305357_A_Case_Series_of_100_COVID-19_Positive_Patients_Treated_with_Combination_of_Ivermectin_and_Doxycycline

Al-Kuraishy, H. et al. Is ivermectin–Azithromycin combination the next step for COVID-19?. Biomed Biotechnol Res J, 2020; vol. 4: S1:101-3
https://www.bmbtrj.org/article.asp?issn=2588-9834;year=2020;volume=4;issue=5;spage=101;epage=103;aulast=Al-Kuraishy

Azam, N. Some home remedies used for treatment of COVID-19 in Bangladesh. Journal of Medicinal Plant Studies. 2020; vol. 8(4): p.27-32
https://www.researchgate.net/publication/344454185_Some_home_remedies_used_for_treatment_of_COVID-19_in_Bangladesh

Bernigaud, C. et al. Bénéfice de l’ivermectine: de la gale à la COVID-19, un exemple de sérendipité. Annales de Dermatologie et de Vénéréologie, 2020; vol. 147 (12): A194
https://www.sciencedirect.com/science/article/pii/S015196382030627X

Caly, L. et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, 2020; vol. 178 (June)
https://www.sciencedirect.com/science/article/pii/S0166354220302011

Camprubi, D. et al. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS ONE, 2020; vol. 15 (11)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0242184

Carvallo, H. Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel. Journal of Biomedical Research and Clinical Investigation, 2020; vol. 2 (1)
https://medicalpressopenaccess.com/upload/1605709669_1007.pdf

Chacar, A. et al. Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients. Internation Journal of Sciences, 2020; vol. 9 (September): p.31-35
https://www.ijsciences.com/pub/article/2378

Espitia-Hernandez, G. Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study. Biomedical Research: An International Journal of Medical Sciences, 2020; vol. 31 (5)
https://www.biomedres.info/biomedical-research/effects-of-ivermectinazithromycincholecalciferol-combined-therapy-on-covid19-infected-patients-a-proof-of-concept-study-14435.html

Fonseca, S. et al. Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis. Travel Medicine and Infectious Diseases, 2020; vol.38
https://www.sciencedirect.com/science/article/pii/S1477893920304026?via%3Dihub

Guerrero, E. et al. COVID-19: The Ivermectin African Enigma. Damage Control Surgery (I), 2020; vol. 51(4)
https://colombiamedica.univalle.edu.co/index.php/comedica/article/view/4613

Guzzo, C. et al. Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects. Journal of Clinical Pharmacology, 2002; vol. 42(10): p.1122-1133
https://www.researchgate.net/publication/11094854_Safety_Tolerability_and_Pharmacokinetics_of_Escalating_High_Doses_of_Ivermectin_in_Healthy_Adult_Subjects

Heidary, F. & R. Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. The Journal of Antibiotics, 2020; vol. 73: p. 593-602
https://www.nature.com/articles/s41429-020-0336-z

Hellwig, M. & A. Maya A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin. International Journal of Antimicrobial Agents, 2020; November
https://www.sciencedirect.com/science/article/pii/S0924857920304684

Hussain, S. Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh. International Journal of Molecular and Immuno Oncology, 2020; December
https://www.researchgate.net/publication/346639384_Outcome_of_ivermectin_and_doxycycline_in_cancer_patients_with_COVID-19_A_positive_experience_in_Bangladesh

Jans, D. & K. Wagstaff Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? Cells, 2020; vol. 9(9)
https://pubmed.ncbi.nlm.nih.gov/32942671/

Kahn, S. et al. Ivermectin for COVID-19: A broad-spectrum veterinary endectocide with antiviral activity. Journal of Food and Animal Sciences, 2020; vol. 1(1): p.1-6
https://www.researchgate.net/publication/344876069_Ivermectin_for_COVID-19_A_broad-spectrum_veterinary_endectocide_with_antiviral_activity

Kaur, H. Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacological Reports, 2021
https://link.springer.com/article/10.1007/s43440-020-00195-y#citeas

Kory, P. et al. Review of .the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. Frontiers in Pharmocology, 2020
https://www.frontiersin.org/articles/10.3389/fphar.2021.643369/abstract

Lehrer, S. & P. Rheinstein Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2. In Vivo, 2020; vol. 34(5): p. 3023-3026
https://iv.iiarjournals.org/content/34/5/3023

Li, N. et al. Quantitative proteomics reveals a broad‐spectrum antiviral property of ivermectin, benefiting for COVID‐19 treatment. Journal of Cellular Physiology, 2020; p.1-17
https://onlinelibrary.wiley.com/doi/10.1002/jcp.30055

Madrid, R. et al. Safety of oral administration of high doses of ivermectin by means of biocompatible polyelectrolytes formulation. Heliyon, 2021; vol. 7(1)
https://www.sciencedirect.com/science/article/pii/S2405844020326633

McCullough, P. et al. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). Reviews in Cardiovascular Medicine, 2020; vol 21 (4): p.517-530
https://www.researchgate.net/publication/348003487_Multifaceted_highly_targeted_sequential_multidrug_treatment_of_early_ambulatory_high-risk_SARS-CoV-2_infection_COVID-19

Mittal, N & R. Mittal. Inhaled route and anti-inflammatory action of ivermectin: Do they hold promise in fighting against COVID-19? Medical Hypotheses, 2020; November
https://www.sciencedirect.com/science/article/pii/S0306987720332552?via%3Dihub

Momekov, G. & D. Momekova Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. Biotechnology & Biotechnological Equipment, 2020; vol. 34 (1)
https://www.tandfonline.com/doi/full/10.1080/13102818.2020.1775118

Mody, V. et al. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Communications Biology, 2021; 4: art. 93
https://www.nature.com/articles/s42003-020-01577-x#citeas

Navarro, M. et al. Safety of high-dose ivermectin: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2020; vol. 75(4): p.827-834
https://academic.oup.com/jac/article-abstract/75/4/827/5710696?redirectedFrom=fulltext

Núñez, A. et al. Therapeutic Efficacy of Ivermectin as an Adjuvant in the Treatment of Patients with COVID-19 Study conducted at the Social Security Institute for Workers of the State of Chiapas, ISSTECH, Mexico. International Journal of Innovative Science and Research Technology, 2020; vol. 5(7): p.211-215
https://ijisrt.com/therapeutic-efficacy-of-ivermectin-as-an-adjuvant-in-the-treatment-of-patients-with-covid19-study-conducted-at-the-social-security-institute-for-workers-of-the-state-of-chiapas-isstech-mexico

Padhy, B. et al. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. Journal of Pharmacy and Pharmaceutical Sciences, 2020; 23: p.462-469
https://pubmed.ncbi.nlm.nih.gov/33227231/

Procter, B. et al. Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Reviews in Cardiovascular Medicine, 2020; vol. 21 (4): p. 611-614
https://pubmed.ncbi.nlm.nih.gov/33388006/

Podder, C.S. Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study. I.M.C. Journal of Medical Science, 2020; vol. 14 (2)
http://imcjms.com/registration/journal_abstract/353

Rajter, J. et al. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The ICON Study. CHEST, 2020; october
https://www.sciencedirect.com/science/article/pii/S0012369220348984

Schmith, V. et al. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clin. Pharmocol Ther., 2020; May
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267287/

Shouman, W. Use of Ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt : A Randomised clinical trial. Journal of Clinical and Diagnostic Research, 2020
https://www.researchgate.net/publication/348755915_Use_of_Ivermectin_as_a_potential_chemoprophylaxis_for_COVID-19_in_Egypt_A_Randomised_clinical_trial

Spoorthi, V & Sasank S. Utility of Ivermectin and Doxycycline combination for the treatment of SARS-CoV-2. IAIM, 2020; vol. 7(10): p.177-182.
http://iaimjournal.com/wp-content/uploads/2020/10/iaim_2020_0710_23.pdf

Surnar, B. Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19. ACS Pharmalogical & Translational Science, 2020; December
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724756/

Preprint studies

Afsar, N. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3734478

Aguirre-Chang, G. et al. Post-Acute or Prolonged COVID-19 Treatment with Ivermectin for Patients with Persistent, or Post-Acute Symptoms
https://www.researchgate.net/publication/344318845_POST-ACUTE_OR_PROLONGED_COVID-19_IVERMECTIN_TREATMENT_FOR_PATIENTS_WITH_PERSISTENT_SYMPTOMS_OR_POST-ACUTE

Aguirre-Chang, G. & A. Figueredo, COVID-19: Pre-exposure Prophylaxis with Ivermectin for exposed people.
https://www.researchgate.net/publication/343650306_COVID-19_Pre-exposure_Prophylaxis_with_Ivermectin_for_exposed_people

Aguirre-Chang, G. et al. COVID-19 Persistent: Treatment with Ivermectin and Acetylsalicylic acid of patients with the persistent syndrome of anosmia or hyposmia
https://www.researchgate.net/publication/344468089_COVID-19_Persistent_TREATMENT_WITH_IVERMECTIN_AND_ACETYLSALICYLIC_ACID_OF_PATIENTS_WITH_THE_PERSISTENT_SYMPTOM_OF_ANOSMIA_OR_HYPOSMIA

Babalola, O. et al. Ivermectin shows clinical benefits in mild to moderate Covid19 disease: A randomised controlled double blind dose response study in Lagos.
https://www.medrxiv.org/content/10.1101/2021.01.05.21249131v1

Behera, P. et al. Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study.
https://www.medrxiv.org/content/10.1101/2020.10.29.20222661v1

Budhiraja, S. et al. Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience
https://www.medrxiv.org/content/10.1101/2020.11.16.20232223v1

Bukhari, K. et al. Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease
https://www.medrxiv.org/content/10.1101/2021.02.02.21250840v1

Cadegiani, F. A. Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients
https://www.medrxiv.org/content/10.1101/2020.10.31.20223883v1

Carvallo, H. Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19.
https://www.medrxiv.org/content/10.1101/2020.09.10.20191619v1

Chamie-Quintero, J. et al. Sharp Reductions in COVID-19 Case Fatalities and Excess Deaths in Peru in Close Time Conjunction, State-By-State, with Ivermectin Treatments
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3765018

Cobos-Campos, R. et al. Potential use of ivermectin for the treatment and profilaxis of SARS-CoV-2 infection: Efficacy of ivermectin for SARS-CoV-2
https://www.oatext.com/potential-use-of-ivermectin-for-the-treatment-and-profilaxis-of-sars-cov-2-infection-efficacy-of-ivermectin-for-sars-cov-2.php#Article&gsc.tab=0

Dias de Melo, G. Anti-COVID-19 efficacy of ivermectin in the golden hamster
https://www.biorxiv.org/content/10.1101/2020.11.21.392639v1

Elgazzer, A. et al. Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic
https://www.researchsquare.com/article/rs-100956/v2

Frances-Monerris, A. et al. Has Ivermectin Virus-Directed Effects against SARS-CoV-2? Rationalizing the Action of a Potential Multitarget Antiviral Agent
https://www.researchgate.net/publication/343563254_Has_Ivermectin_Virus-Directed_Effects_against_SARS-CoV-2_Rationalizing_the_Action_of_a_Potential_Multitarget_Antiviral_Agent

Gorial, F.I. et al. Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)
https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1

Hashim, H.A. et al. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq
https://www.medrxiv.org/content/10.1101/2020.10.26.20219345v1

Hill, A. et al. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection
https://www.researchsquare.com/article/rs-148845/v1

Jeffreys, L. et al. Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2
https://www.biorxiv.org/content/10.1101/2020.12.23.424232v1

Kalfas, S. et al. The Therapeutic Potential of Ivermectin for COVID-19: a systematic review of Mechanisms and Evididence.
https://www.medrxiv.org/content/10.1101/2020.11.30.20236570v1.full-text

Kirty, R. et al. Ivermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled trial
https://www.medrxiv.org/content/10.1101/2021.01.05.21249310v1

Krolewiecki, A. et al. Antiviral Effect of High-Dose Ivermectin in Adults with COVID-19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3714649

Lawrie, T. Ivermectin reduces the risk of death from COVID-19 -a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance.
https://www.researchgate.net/publication/348297284_Ivermectin_reduces_the_risk_of_death_from_COVID-19_-a_rapid_review_and_meta-analysis_in_support_of_the_recommendation_of_the_Front_Line_COVID-19_Critical_Care_Alliance_Latest_version_v12_-_6_Jan_2021

Mohan, A. et al. Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial.
https://www.researchgate.net/publication/348989048_Ivermectin_in_mild_and_moderate_COVID-19_RIVET-COV_a_randomized_placebo-controlled_trial

Morgenstern, J. et al. The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020
https://www.medrxiv.org/content/10.1101/2020.10.29.20222505v1

Niaee, M.S. et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial
https://www.researchsquare.com/article/rs-109670/v1

Soto-Becarra, P. et al. Real-world effectiveness  Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Studyof hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru
https://www.medrxiv.org/content/10.1101/2020.10.06.20208066v3

Swargiary, A. Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies.
https://www.researchsquare.com/article/rs-73308/v1

Turkia, M. FLCCC Alliance MATH+ ascorbic acid and I-MASK+ ivermectin protocols for COVID-19 – A Brief Review
https://www.researchgate.net/publication/345694745_FLCCC_Alliance_MATH_ascorbic_acid_and_I-MASK_ivermectin_protocols_for_COVID-19_-_A_Brief_Review

Clinical Trials met resultaten

Chala, R. Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan (Ivercar-Tuc). 2021
https://www.researchgate.net/publication/345694745_FLCCC_Alliance_MATH_ascorbic_acid_and_I-MASK_ivermectin_protocols_for_COVID-19_-_A_Brief_Review

Mahmud, R, Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection. 2020
https://clinicaltrials.gov/ct2/show/results/NCT04523831?view=results

Okomuş, N. Ivermectin for servere COVID-19 management. 2020
https://clinicaltrials.gov/ct2/show/NCT04646109

Raad, H. In vivo use of ivermectin (IVR) for treatment for corona virus infected patients (COVID-19): a randomized controlled trial. 2020
http://www.chictr.org.cn/showprojen.aspx?proj=54707

Shouman, W. M.  Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contacts with Patients of COVID-19. 2020
https://clinicaltrials.gov/ProvidedDocs/61/NCT04422561/Prot_SAP_000.pdf

Review article

Frediansyah, A. et al. Antivirals for COVID-19: A critical review. Clinical Epidemiology and Global Health, 2020; vol. 9: p. 90-98
https://www.sciencedirect.com/science/article/pii/S2213398420301767

Scientific Letters

Khan, S. et al. Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19. Archivos de Bronconeumología, 2020; vol. 56 (12): p. 828-830
https://www.sciencedirect.com/science/article/pii/S030028962030288X

Pandey, S. et al. Ivermectin in COVID-19: What do we know? Diabetes & Metabolic Syndrome: Research & Reviews, 2020; vol. 14 (6): p. 1921-1922
https://www.sciencedirect.com/science/article/pii/S1871402120303799

Letter to the editor

Gupta, D. et al. Ivermectin: potential candidate for the treatment of Covid 19. The Brazilian Journal of Infectious Diseases, 2020; vol. 24 (4): p. 369 -371
https://www.bjid.org.br/en-ivermectin-potential-candidate-for-treatment-articulo-S1413867020300817

DiNicolantonia, J. et al. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. Open Heart, 2020; vol. 7(4)
https://openheart.bmj.com/content/7/2/e001350

Pena-Silva, R. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID‐19. British Journal of Clinical Pharmocology. 2020
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404744/

Rizzo, E. Ivermectin, Antiviral properties and COVID-19: a possible new mechanism of action. Naunyn-Schmiedeberg´s Archives of Pharmacology, 2020; July, 393 (7): p. 1153-1156.
https://pubmed.ncbi.nlm.nih.gov/32462282/

Vora, A. et al. White paper on Ivermectin as a potential therapy for COVID-19. Indian Journal on Tuberculosis, 2020; vol. 67(3): p.448-451
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434458/

ClaimedIn © 2021. Alle Rechten Voorbehouden

Disclaimer: Petities geven niet per definitie de mening van ClaimedIn weer